Chemotherapy-Induced Apoptosis in a Transgenic Model of Neuroblastoma Proceeds Through p53 Induction

Maris, 1999, Molecular biology of neuroblastoma, J Clin Oncol, 17, 2264, 10.1200/JCO.1999.17.7.2264 Matthay, 1999, Treatment of highrisk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group, N Engl J Med, 341, 1165, 10.1056/NEJM199910143411601 Schmidt, 2000, Biologic factors determine prognosis in infants with stage IV neuroblastoma: a prospective Children's Cancer Group Study, J Clin Oncol, 18, 1260, 10.1200/JCO.2000.18.6.1260 Brodeur, 1985, Amplification of N-myc sequences in primary human neuroblastomas: correlation with advanced disease stage, Prog Clin Biol Res, 175, 105 Seeger, 1985, Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas, N Engl J Med, 313, 1111, 10.1056/NEJM198510313131802 Fulda, 1999, MycN sensitizes neuroblastoma cells for drug-induced apoptosis, Oncogene, 18, 1479, 10.1038/sj.onc.1202435 van Noesel, 2003, The N-myc paradox: N-myc overexpression in neuroblastomas is associated with sensitivity as well as resistance to apoptosis, Cancer Lett, 197, 165, 10.1016/S0304-3835(03)00101-0 Lutz, 1996, Conditional expression of N-myc in human neuroblastoma cells increases expression of alpha-prothymosin and ornithine decarboxylase and accelerates progression into S-phase early after mitogenic stimulation of quiescent cells, Oncogene, 13, 803 Keshelava, 1997, Drug resistance in human neuroblastoma cell lines correlates with clinical therapy, Eur J Cancer, 33, 2002, 10.1016/S0959-8049(97)00213-X Keshelava, 1998, Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy, Cancer Res, 58, 5396 Carr, 2006, Increased frequency of aberrations in the p53/MDM2/p14(ARF) pathway in neuroblastoma cell lines established at relapse, Cancer Res, 66, 2138, 10.1158/0008-5472.CAN-05-2623 Tweddle, 2001, Evidence for the development of p53 mutations after cytotoxic therapy in a neuroblastoma cell line, Cancer Res, 61, 8 Islam, 2000, High expression survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma, Oncogene, 19, 617, 10.1038/sj.onc.1203358 Eggert, 2000, Resistance to TRAIL-induced apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression, Med Pediatr Oncol, 35, 603, 10.1002/1096-911X(20001201)35:6<603::AID-MPO24>3.0.CO;2-1 Teitz, 2000, Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN, Nat Med, 6, 529, 10.1038/75007 Castle, 1993, Expression of the apoptosis-suppressing protein bcl-2, in neuroblastoma is associated with unfavorable histology and N-myc amplification, Am J Pathol, 143, 1543 Mora, 2001, Genetic heterogeneity and clonal evolution in neuroblastoma, Br J Cancer, 85, 182, 10.1054/bjoc.2001.1849 Teitz, 2001, Aggressive childhood neuroblastomas do not express caspase-8: an important component of programmed cell death, J Mol Med, 79, 428, 10.1007/s001090100233 Norris, 1997, Evidence that the MYCN oncogene regulates MRP gene expression in neuroblastoma, Eur J Cancer, 33, 1911, 10.1016/S0959-8049(97)00284-0 Weiss, 1997, Targeted expression of MYCN causes neuroblastoma in transgenic mice, EMBO J, 16, 2985, 10.1093/emboj/16.11.2985 Norris, 2000, Expression of N-myc and MRP genes and their relationship to N-myc gene dosage and tumor formation in a murine neuroblastoma model, Med Pediatr Oncol, 35, 585, 10.1002/1096-911X(20001201)35:6<585::AID-MPO20>3.0.CO;2-P Maris, 2000, Loss of heterozygosity at 1p36 independently predicts for disease progression, but not decreased overall survival probability, in neuroblastoma patients: a Children's Cancer Group Study, J Clin Oncol, 18, 1888, 10.1200/JCO.2000.18.9.1888 Keshelava, 2000, p53 mutations and loss of p53 function confer multidrug resistance in neuroblastoma, Med Pediatr Oncol, 35, 563, 10.1002/1096-911X(20001201)35:6<563::AID-MPO15>3.0.CO;2-J Keshelava, 2001, Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines, Cancer Res, 61, 6185 Donehower, 1992, Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours, Nature, 356, 215, 10.1038/356215a0 Momota, 2005, Bioluminescence technology for imaging cell proliferation, Curr Opin Biotechnol, 16, 681, 10.1016/j.copbio.2005.10.012 Jeffers, 2003, Puma is an essential mediator of p53-dependent and -independent apoptotic pathways, Cancer Cell, 4, 321, 10.1016/S1535-6108(03)00244-7 Fulda, 2000, MycN sensitizes neuroblastoma cells for drug-triggered apoptosis, Med Pediatr Oncol, 35, 582, 10.1002/1096-911X(20001201)35:6<582::AID-MPO19>3.0.CO;2-2 Reed, 1991, Differential expression of bcl2 protooncogene in neuroblastoma and other human tumor cell lines of neural origin, Cancer Res, 51, 6529 Dansen, 2006, Specific requirement for Bax, not Bak, in Myc-induced apoptosis and tumor suppression in vivo, J Biol Chem, 281, 10890, 10.1074/jbc.M513655200 Hemann, 2004, Suppression of tumorigenesis by the p53 target PUMA, Proc Natl Acad Sci USA, 101, 9333, 10.1073/pnas.0403286101 Chipuk, 2005, PUMA couples the nuclear and cytoplasmic proapoptotic function of p53, Science, 309, 1732, 10.1126/science.1114297 Xue, 2007, p53 determines multidrug sensitivity of childhood neuroblastoma, Cancer Res, 67, 10351, 10.1158/0008-5472.CAN-06-4345 Armstrong, 2006, Signaling from p53 to NF-kappa B determines the chemotherapy responsiveness of neuroblastoma, Neoplasia, 8, 964, 10.1593/neo.06574